An international leader in lung cancer clinical trials research with particular expertise in drug development for thoracic malignancies and immunotherapy, Dr. Julie Brahmer currently serves as Director of the Thoracic Oncology Program and Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, as well as Interim Director of the Johns Hopkins Kimmel Cancer Center at Bayview in Baltimore, MD. In addition, she serves as co-Principal Investigator on the Johns Hopkins’ NCI National Clinical Trials Network (NCTN) Program grant and helps direct all oncology cooperative group activities on the Johns Hopkins campuses.
Dr. Brahmer's research and clinical practice focus on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. She has published several papers in this area of research and is a member of the American Society of Clinical Oncology (ASCO) and the Eastern Cooperative Oncology Group Thoracic Committee and Cancer Prevention Steering Committee. Dr. Brahmer is one of the founding board members for the National Lung Cancer Partnership, now known as Free to Breathe, where she is a member of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Foundation and LUNGevity.
Dr. Brahmer was the 2012 recipient of the ASCO Statesman Award for her volunteer efforts to the society. In the summer of 2014, she was featured in MORE magazine for her cutting edge research in the groundbreaking field of cancer immunotherapy. As a result of her work, she was named the March 2015 LUNGevity Hero and, in November 2015, received the Dr. Thierry Jahan “A Breath Away from the Cure” Award.
Dr. Brahmer has been intimately involved in the development of anti-PD-1 antibodies as PI of several early phase I studies of these antibodies and phase III studies in lung cancer. These trials led to the FDA approval of the first immunotherapy option in lung cancer, nivolumab. She is committed to the research and development of effective immune-based therapies in the treatment of lung cancer and other cancers such as mesothelioma.
Dr. Brahmer received her Medical Degree from the University of Nebraska Medical Center College of Medicine in Omaha, NE, and completed her residency at the University of Utah and Oncology fellowship at Johns Hopkins.
- Director, Thoracic Oncology Program
Interim Director, Johns Hopkins Kimmel Cancer Center at Bayview
Associate Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins School of Medicine